°â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, ¿¬·ÉÃþº°, Åõ¿© °æ·Îº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åë ä³Îº°, Áö¿ªº°
Sickle Cell Disease Treatment Market, By Treatment Type, By Age Group, By Route of Administration, By End User, By Distribution Channel, By Geography
»óǰÄÚµå : 1671873
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀåÀº 2025³â¿¡ 32¾ï ´Þ·¯, 2032³â¿¡´Â 88¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 15.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 32¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 15.6% 2032³â °¡Ä¡ ¿¹Ãø 88¾ï 1,000¸¸ ´Þ·¯
±×¸². °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2025³â
Sickle Cell Disease Treatment Market-IMG1

°â»ó ÀûÇ÷±¸ ÁúȯÀº ºñÁ¤»óÀûÀÎ ÀûÇ÷±¸¸¦ À¯¹ßÇÏ´Â À¯Àü¼º Ç÷¾× ÁúȯÀÔ´Ï´Ù. ü³» Á¶Á÷°ú Àå±â¿¡ »ê¼Ò °ø±Þ¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ ÁúȯÀº Àü ¼¼°è, ƯÈ÷ »çÇ϶ó À̳² ¾ÆÇÁ¸®Ä«, Áßµ¿, Àεµ ¾Æ´ë·ú, ÁöÁßÇØ Áö¿ª, Áß³²¹Ì µîÁö¿¡¼­ À¯ÇàÇϰí ÀÖ½À´Ï´Ù. Áø´Ü ¹× ¹ß°ß·ü Áõ°¡¿Í ´õºÒ¾î °í±Þ Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÇâÈÄ ¸î ³âµ¿¾È ½ÃÀåÀº À¯¸®ÇÑ ±âȸ¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »õ·Î¿î ¾à¹° ¿ä¹ý ¹× À¯ÀüÀÚ Ä¡·á ±â¹Ý Ä¡·á Á¢±Ù¹ýÀÇ °³¹ßµµ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

½Å¾à ¹× ÇâÈÄ ÆÄÀÌÇÁ¶óÀÎ Èĺ¸¹°Áú °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ Ȱµ¿ÀÌ È°¹ßÇØÁö¸é¼­ ¼¼°è °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÅÈï±¹ÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í À¯¸®ÇÑ »óȯ Á¤Ã¥Àº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °ñ¼ö À̽İú °°Àº ±Ùº»ÀûÀÎ Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÷´Ü Ä¡·á Á¢±Ù¹ý¿¡ µû¸¥ ³ôÀº ºñ¿ë°ú Àú°³¹ß Áö¿ª¿¡¼­ÀÇ ³·Àº ÀÎÁöµµ´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á ±â¹Ý Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½ÃÀå Âü¿©Àڵ鿡°Ô Å« ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àú·ÅÇÑ °¡°ÝÀÇ Àç»ý Ä¡·á ¿É¼ÇÀÇ °³¹ßÀº °¡±î¿î ¹Ì·¡¿¡ »õ·Î¿î ±æÀ» ¿­ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.

¼¼°è °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀ» ±â¾÷ ¼Ò°³, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

½ÃÀå ÁÖ¿ä ±â¾÷À¸·Î´Â Novartis AG, Emmaus Medical Inc., Agios Pharmaceuticals Inc, Bluebird Bio, Pfizer Inc. Corporation, GSK(GlaxoSmithKline), Sanofi S.A., Merck &Co., Amgen Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è °â»ó ÀûÇ÷±¸Áõ Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, Ä¡·á À¯Çüº°, 2020³â-2032³â

Á¦5Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, ¿¬·É ±×·ìº°, 2020³â-2032³â

Á¦6Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2020³â-2032³â

Á¦7Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â

Á¦8Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â

Á¦9Àå ¼¼°èÀÇ °â»ó ÀûÇ÷±¸ Áúȯ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020³â-2032³â

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.20 Bn in 2025 and is expected to reach USD 8.81 Bn by 2032 exhibiting a compound annual growth rate (CAGR) of 15.6% from 2025 to 2032

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 3.20 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 15.60% 2032 Value Projection: USD 8.81 Bn
Figure. Sickle Cell Disease Treatment Market Share (%), By Region, 2025
Sickle Cell Disease Treatment Market - IMG1

Sickle cell disease is a genetic blood disorder causing abnormal red blood cells. It affects the oxygen supply to tissues and organs in the body. This disorder is prevalent across worldwide, especially in Sub-Saharan Africa, the Middle East, Indian subcontinent, Mediterranean regions, and South and Central America. With growing diagnostic and detection rates, coupled with rising awareness regarding availability of advanced treatment options, the market is projected to showcase lucrative opportunities over the coming years. The development of new drug therapies and gene-therapy based treatment approaches are also fueling the market expansion.

Market Dynamics:

Increasing research activities focusing on developing novel drugs and upcoming pipeline candidates are acting as a key growth driver for global sickle cell disease treatment market. Rising healthcare expenditures in emerging nations and favorable reimbursement policies are further supporting the market growth. Growing adoption of curative therapies such as bone marrow transplantation is also boosting the market. However, high costs associated with advanced treatment approaches and lack of awareness in underdeveloped regions are restraining the market growth. Rising adoption of gene-therapy based treatments presents significant opportunities for market players. Development of affordable regenerative treatment options also holds potential to create new avenues in the near future.

Key Features of the Study:

This report provides in-depth analysis of the global sickle cell disease treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global sickle cell disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Novartis AG, Emmaus Medical Inc., Agios Pharmaceuticals Inc., Bluebird Bio, Pfizer Inc., Bristol-Myers Squibb Company, Celgene Corporation, GSK (GlaxoSmithKline), Sanofi S.A., Merck & Co., Inc., Amgen Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Company, Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global sickle cell disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sickle cell disease treatment market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Sickle Cell Disease Treatment Market, By Treatment Type, 2020-2032, (USD Bn)

5. Global Sickle Cell Disease Treatment Market, By Age Group, 2020-2032, (USD Bn)

6. Global Sickle Cell Disease Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

7. Global Sickle Cell Disease Treatment Market, By End User, 2020-2032, (USD Bn)

8. Global Sickle Cell Disease Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

9. Global Sickle Cell Disease Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â